2016
DOI: 10.3109/0284186x.2016.1167959
|View full text |Cite
|
Sign up to set email alerts
|

Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials

Abstract: Technical validation of the 15-gene hypoxia classifier demonstrated that it is suitable for implementation in prospective clinical trials.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
55
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 56 publications
(57 citation statements)
references
References 27 publications
2
55
0
Order By: Relevance
“…Apart from the inter-patient variations, an intra-tumor heterogeneity in treatment response is observed. The tissue-based biomarkers from tumor biopsies may not account for intra-tumor heterogeneity, except for selected markers and marker profiles [7], and thus other approaches should be investigated.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Apart from the inter-patient variations, an intra-tumor heterogeneity in treatment response is observed. The tissue-based biomarkers from tumor biopsies may not account for intra-tumor heterogeneity, except for selected markers and marker profiles [7], and thus other approaches should be investigated.…”
Section: Introductionmentioning
confidence: 99%
“…Radiomics is a method for quantitative analysis of medical images [7,8]. It provides tools for comprehensive image analysis on different scales: shape, intensity, texture and transform-based analysis.…”
Section: Introductionmentioning
confidence: 99%
“…In addition to radiation-induced gene response signatures, other groups have looked at signatures that may predict response to radiation treatment for a range of different cancer types. These gene expression profiles include hypoxia-related signatures (72)(73)(74), cell cycle and DNA damage gene-related signatures (75,76), along with signatures predicting response to radiosensitising drugs (77,78). As with many of the other in vitro derived signatures, none of these has thus far withstood stringent external validation and therefore have yet to be translated into clinical practice.…”
Section: Pan-cancer Genomic Signaturesmentioning
confidence: 99%
“…The second signature is the 15-gene hypoxia classifier, first described between 2010 and 2011 [84,85] and then validated as prognostic signature in retrospective series [86]. A patent application is currently pending on this method for determination of clinically relevant hypoxia in cancer specimen (WO/2012/146259).…”
Section: Analysis Of Recent Epigenomics and Transcriptomics Datamentioning
confidence: 99%